Pensionfund Sabic increased its position in Humana Inc (NYSE:HUM) by 11.7% in the second quarter, Holdings Channel reports. The firm owned 6,700 shares of the insurance provider’s stock after purchasing an additional 700 shares during the quarter. Pensionfund Sabic’s holdings in Humana were worth $1,778,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of HUM. Pacer Advisors Inc. lifted its holdings in Humana by 6,493.6% in the first quarter. Pacer Advisors Inc. now owns 12,396 shares of the insurance provider’s stock worth $3,298,000 after acquiring an additional 12,208 shares during the last quarter. Machina Capital S.A.S. bought a new position in Humana in the fourth quarter worth about $809,000. World Asset Management Inc lifted its holdings in Humana by 10.9% in the first quarter. World Asset Management Inc now owns 10,840 shares of the insurance provider’s stock worth $2,883,000 after acquiring an additional 1,067 shares during the last quarter. Cribstone Capital Management LLC bought a new position in Humana in the first quarter worth about $230,000. Finally, Deutsche Bank AG lifted its holdings in Humana by 13.8% in the fourth quarter. Deutsche Bank AG now owns 470,987 shares of the insurance provider’s stock worth $134,923,000 after acquiring an additional 57,106 shares during the last quarter. Institutional investors and hedge funds own 92.62% of the company’s stock.
Several research firms recently issued reports on HUM. SunTrust Banks lifted their price objective on shares of Markel to $1,100.00 and gave the company a “hold” rating in a research note on Thursday, May 2nd. Citigroup downgraded shares of BCE from a “buy” rating to a “neutral” rating in a report on Thursday, May 2nd. ValuEngine raised shares of Valmont Industries from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Credit Suisse Group reissued a “buy” rating and issued a $19.50 price target on shares of Infineon Technologies in a report on Thursday, May 2nd. Finally, Zacks Investment Research downgraded shares of Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $336.42.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.30 by $0.18. The business had revenue of $16.11 billion for the quarter, compared to the consensus estimate of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. The company’s revenue was up 12.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.36 earnings per share. On average, research analysts expect that Humana Inc will post 17.48 earnings per share for the current fiscal year.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: How to trade on quiet period expirations
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.